May 28, 2026 —
Shanghai-based YolTech Therapeutics has raised $70 million in Series C funding to support its expanding clinical pipeline of in vivo gene editing therapies. The financing nearly doubles the company’s total capital raised to more than $156 million since its founding in 2021 and comes as YolTech prepares for a potential Hong Kong IPO.
The round included new investors such as Loyal Valley Capital and CPIC Capital, with participation from returning investors including K2VC and Grand Flight. According to the company, the financing was significantly oversubscribed and is intended to support multiple clinical programs in China, as well as possible expansion into the United States.
YolTech has become one of China’s most active gene editing companies, bringing six CRISPR-based therapies into clinical development. Its pipeline spans several major therapeutic areas, including alpha-1 antitrypsin deficiency, transthyretin amyloidosis, primary hyperoxaluria type 1, beta-thalassemia, and future programs in in vivo CAR-T and lipoprotein(a) reduction.
One of YolTech’s most globally competitive programs is its base editing therapy for alpha-1 antitrypsin deficiency. Because the target mutation is rare in China, the company expects to conduct trials in Europe and the United States. Two European patients have already been treated in Shanghai, and early data showed enzyme levels restored to more than 20 μM, exceeding the commonly referenced 11 μM protective threshold. The FDA has cleared YolTech to move directly into a Phase 2/3 trial in the United States based in part on data generated in China.
YolTech’s most advanced program targets transthyretin amyloidosis, where the company is approaching one-year follow-up from the last patient in its Phase 2 study. The company plans to seek approval from Chinese regulators to begin a Phase 3 trial, which it says could become the first in vivo gene editing program to enter Phase 3 in China. It is also developing a second-generation ATTR candidate with a different editing enzyme and LNP formulation, designed to achieve deeper TTR reduction at a lower dose.
The company has also advanced programs in primary hyperoxaluria type 1 and beta-thalassemia. In PH1, YolTech has dosed more than 10 patients in China and is planning a global pivotal study, including U.S. sites. In beta-thalassemia, YolTech is developing an in vivo gene editing approach that may offer a more convenient alternative to ex vivo cell therapies, with early clinical signs suggesting activation of fetal hemoglobin.
YolTech’s rapid pipeline expansion highlights China’s growing role in the global gene editing landscape. While many U.S. gene editing companies have narrowed their pipelines, YolTech is moving multiple in vivo editing programs forward simultaneously and may become a major global competitor in areas where clinical-stage programs remain limited.
